

L1 9336 S GNRH(W)AGONIST
L2 166220 S PROSTATE(W)CANCER
L3 377 S L1 AND L2
L4 1342 S (SHH OR HEDGEHOG)(W) (SIGNALING OR SIGNALLING)(W) PATHWAY
L5 0 S L3 AND L4
L6 28 S L2 AND L4
L7 140 S L3 AND TESTOSTERONE
L8 1238 S CYCLOPAMINE
L9 0 S L3 AND L8
L10 0 S JERVAINE
L11 592 S JERVINE
L12 1238 S L1 AND L11 OR L8
L13 0 S L1 AND L11
L14 2 S L1 AND L8
L15 2 S L1 AND (L11 OR L8)
L16 39 S DEOXOJERVINE
L17 0 S L16 AND L1
L18 0 S L7 AND (L11 OR L8 OR L16)
L19 54 S L2 AND (L11 OR L8 OR L16)
L20 27 S L19 AND TREATMENT

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:08:57 ON 11 MAY 2007
ENTER COST CENTER (NONE) :none

FILE 'MEDLINE' ENTERED AT 13:09:15 ON 11 MAY 2007

FILE 'BIOSIS' ENTERED AT 13:09:15 ON 11 MAY 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 13:09:15 ON 11 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:09:15 ON 11 MAY 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 13:09:15 ON 11 MAY 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s gnrh(w) agonist
L1 9336 GNRH(W) AGONIST

=> s prostate(w) cancer
L2 166220 PROSTATE(W) CANCER

=> s 11 and 12
L3 377 L1 AND L2

=> s (shh or h)

L4 1342 (SHH OR H

L5 0 L3 AND L4

L6 28 L2 AND L4

L7 140 L3 AND TESTOSTERONE

L8 1238 CYCLOPAMINE

L9 0 L3 AND L8

=> s je valide

L10 0 JERVAINE

=> s jervine

L11 592 JERVINE

=> s l1 and l11 or l8

L12 1238 L1 AND L11 OR L8

=> s l1 and l11

L13 0 L1 AND L11

=> s l1 and l8

L14 2 L1 AND L8

=> s l1 and (l11 or l8)

L15 2 L1 AND (L11 OR L8)

=> d l15 1-2 ibib

L15 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267240 CAPLUS

DOCUMENT NUMBER: 140:281368

TITLE: An inhibitor of the sonic hedgehog (SHH) signaling pathway and a testosterone suppressing agent for the treatment of cancer

INVENTOR(S): Thomson, Axel Andreas

PATENT ASSIGNEE(S): Medical Research Council, UK

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026304	A1	20040401	WO 2003-GB4117	20030917
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003267623	A1	20040408	AU 2003-267623	20030917
EP 1549308	A1	20050706	EP 2003-748315	20030917
EP 1549308	B1	20060809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503055	T	20060126	JP 2004-537316	20030917
AT 335478	T	20060915	AT 2003-748315	20030917
US 2006094660	A1	20060504	US 2005-528267	20050923
PRIORITY APPLN. INFO.:			GB 2002-21539	A 20020917
			WO 2003-GB4117	W 20030917
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L15 ANSWER 2 OF 2 TOXCENTER COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:80104 TOXCENTER

COPYRIGHT: Copyright 2007 ACS

DOCUMENT NUMBER: CA14018281368X

TITLE: An inhibitor of the sonic hedgehog (SHH) signaling pathway and a testosterone suppressing agent for the treatment of cancer
AUTHOR(S): Thomson, Axel Andreas
CORPORATE SOURCE: ASSIGNEE: Medical Research Council
PATENT INFORMATION: WO 2004026304 A1 1 Apr 2004
SOURCE: (2004) PCT Int. Appl., 78 pp.
CODEN: PIXXD2.
COUNTRY: UNITED KINGDOM
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2004:267240
LANGUAGE: English
ENTRY DATE: Entered STN: 6 Apr 2004
Last Updated on STN: 21 Feb 2006

=> s deoxojervine
L16 39 DEOXOJERVINE

=> d his

(FILE 'HOME' ENTERED AT 13:08:57 ON 11 MAY 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, TOXCENTER' ENTERED AT 13:09:15 ON
11 MAY 2007

L1 9336 S GNRH(W)AGONIST
L2 166220 S PROSTATE(W)CANCER
L3 377 S L1 AND L2
L4 1342 S (SHH OR HEDGEHOG) (W) (SIGNALING OR SIGNALLING) (W) PATHWAY
L5 0 S L3 AND L4
L6 28 S L2 AND L4
L7 140 S L3 AND TESTOSTERONE
L8 1238 S CYCLOPAMINE
L9 0 S L3 AND L8
L10 0 S JERVAINE
L11 592 S JERVINE
L12 1238 S L1 AND L11 OR L8
L13 0 S L1 AND L11
L14 2 S L1 AND L8
L15 2 S L1 AND (L11 OR L8)
L16 39 S DEOXOJERVINE

=> s l16 and l1
L17 0 L16 AND L1

=> d 16 1-28 ibib

L6 ANSWER 1 OF 28 MEDLINE on STN
ACCESSION NUMBER: 2007097632 MEDLINE
DOCUMENT NUMBER: PubMed ID: 17296352
TITLE: Hedgehog signaling in the prostate.
AUTHOR: Shaw Aubie; Bushman Wade
CORPORATE SOURCE: McArdle Laboratory for Cancer Research and Department of
Surgery, University of Wisconsin, Madison, Wisconsin 53792,
USA.
CONTRACT NUMBER: CA095386 (NCI)
SOURCE: The Journal of urology, (2007 Mar) Vol. 177, No. 3, pp.
832-8. Ref: 42
Journal code: 0376374. ISSN: 0022-5347.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)

General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200704
ENTRY DATE: Entered STN: 14 Feb 2007
Last Updated on STN: 4 Apr 2007
Entered Medline: 3 Apr 2007

L6 ANSWER 2 OF 28 MEDLINE on STN
ACCESSION NUMBER: 2006440833 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16750652
TITLE: Perlecan signaling: helping hedgehog stimulate prostate cancer growth.
AUTHOR: Datta Sumana; Pierce Michael; Datta Milton W
CORPORATE SOURCE: Department of Biochemistry and Biophysics, MS 2128, Texas A&M University, College Station, TX 77843-2128, United States.. sumad@tamu.edu
SOURCE: The international journal of biochemistry & cell biology, (2006) Vol. 38, No. 11, pp. 1855-61. Electronic Publication: 2006-04-25. Ref: 19
Journal code: 9508482. ISSN: 1357-2725.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200609
ENTRY DATE: Entered STN: 26 Jul 2006
Last Updated on STN: 19 Sep 2006
Entered Medline: 18 Sep 2006

L6 ANSWER 3 OF 28 MEDLINE on STN
ACCESSION NUMBER: 2006265610 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16374524
TITLE: A mouse prostate cancer model induced by Hedgehog overexpression.
AUTHOR: Chen Bo-Yie; Lin David Pei-Cheng; Liu Jer-Yuh; Chang Han; Huang Po-Hsuan; Chen Yie-Ling; Chang Han-Hsin
CORPORATE SOURCE: Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
SOURCE: Journal of biomedical science, (2006 May) Vol. 13, No. 3, pp. 373-84. Electronic Publication: 2005-12-23.
Journal code: 9421567. ISSN: 1021-7770.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200608
ENTRY DATE: Entered STN: 13 May 2006
Last Updated on STN: 29 Aug 2006
Entered Medline: 28 Aug 2006

L6 ANSWER 4 OF 28 MEDLINE on STN
ACCESSION NUMBER: 2006167437 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16556007
TITLE: Hedgehog signaling in prostate cancer.
AUTHOR: Xie Jingwu
CORPORATE SOURCE: University of Texas Medical Branch at Galveston, Sealy Centers for Cancer Cell Biology and Environmental Health, Department of Pharmacology and Toxicology, 301 University Blvd, Galveston, TX 77555-1048, USA.. jinxie@utmb.edu
SOURCE: Future oncology (London, England), (2005 Jun) Vol. 1, No. 3, pp. 331-8. Ref: 37
Journal code: 101256629. ISSN: 1479-6694.

PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200605
ENTRY DATE: Entered STN: 25 Mar 2006
Last Updated on STN: 12 May 2006
Entered Medline: 11 May 2006

L6 ANSWER 5 OF 28 MEDLINE on STN
ACCESSION NUMBER: 2005018516 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15645142
TITLE: Identification and characterization of rat Desert hedgehog and Indian hedgehog genes in silico.
AUTHOR: Katoh Yuriko; Katoh Masaru
CORPORATE SOURCE: M and M Medical BioInformatics, Hongo 113-0033, Japan.
SOURCE: International journal of oncology, (2005 Feb) Vol. 26, No. 2, pp. 545-9.
Journal code: 9306042. ISSN: 1019-6439.

PUB. COUNTRY: Greece
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200507
ENTRY DATE: Entered STN: 13 Jan 2005
Last Updated on STN: 27 Jul 2005
Entered Medline: 26 Jul 2005

L6 ANSWER 6 OF 28 MEDLINE on STN
ACCESSION NUMBER: 2000033603 MEDLINE
DOCUMENT NUMBER: PubMed ID: 10564661
TITLE: Characterization of the human suppressor of fused, a negative regulator of the zinc-finger transcription factor Gli.
AUTHOR: Stone D M; Murone M; Luoh S; Ye W; Armanini M P; Gurney A; Phillips H; Brush J; Goddard A; de Sauvage F J; Rosenthal A
CORPORATE SOURCE: Departments of Neuroscience, Genentech, Inc. 1 DNA Way, South San Francisco, CA 94080, USA.
SOURCE: Journal of cell science, (1999 Dec) Vol. 112 (Pt 23), pp. 4437-48.
Journal code: 0052457. ISSN: 0021-9533.

PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AF144231; GENBANK-AF159447; GENBANK-AF222345
ENTRY MONTH: 200002
ENTRY DATE: Entered STN: 9 Feb 2000
Last Updated on STN: 9 Feb 2000
Entered Medline: 3 Feb 2000

L6 ANSWER 7 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:206502 BIOSIS
DOCUMENT NUMBER: PREV200700206879
TITLE: Hedgehog signaling in the prostate.
AUTHOR(S): Shaw, Aubie; Bushman, Wade [Reprint Author]
CORPORATE SOURCE: Univ Wisconsin, Dept Surg, 600 Highland Ave, Madison, WI 53792 USA
bushman@surgery.wisc.edu
SOURCE: Journal of Urology, (MAR 2007) Vol. 177, No. 3, pp. 832-838.
CODEN: JOURAA. ISSN: 0022-5347.
DOCUMENT TYPE: Article

LANGUAGE: General Review; (Literature Review)
ENTRY DATE: English
Entered STN: 21 Mar 2007
Last Updated on STN: 21 Mar 2007

L6 ANSWER 8 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2006:560898 BIOSIS
DOCUMENT NUMBER: PREV200600559104
TITLE: Perlecan signaling: Helping hedgehog stimulate
prostate cancer growth.
AUTHOR(S): Datta, Surnana [Reprint Author]; Pierce, Michael; Datta,
Milton W.
CORPORATE SOURCE: Emory Univ, Sch Med, Winship Canc Ctr, Dept Urol, 1365-B
Clifton Rd NE, Room B4202, Atlanta, GA 30322 USA
sumad@tamu.edu; hawkeye@uga.edu; mdatta@emory.edu
SOURCE: International Journal of Biochemistry & Cell Biology,
(2006) Vol. 38, No. 11, pp. 1855-1861.
ISSN: 1357-2725.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 27 Oct 2006
Last Updated on STN: 27 Oct 2006

L6 ANSWER 9 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2006:533880 BIOSIS
DOCUMENT NUMBER: PREV200600520701
TITLE: Targeting the **hedgehog signaling**
pathway with small molecules.
AUTHOR(S): Kiselyov, Alex S. [Reprint Author]
CORPORATE SOURCE: ChemDiv Inc, Small Med Drug Discovery, 11558 Sorrento
Valley Rd, Suite 5, San Diego, CA 92121 USA
ask@chemdiv.com
SOURCE: Anti-Cancer Agents in Medicinal Chemistry, (SEP 2006) Vol.
6, No. 5, pp. 445-449.
ISSN: 1871-5206.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Oct 2006
Last Updated on STN: 12 Oct 2006

L6 ANSWER 10 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN
ACCESSION NUMBER: 2006:467809 BIOSIS
DOCUMENT NUMBER: PREV200600471284
TITLE: A mouse **prostate cancer** model induced
by Hedgehog overexpression.
AUTHOR(S): Chen, Bo-Yie; Lin, David Pei-Cheng; Liu, Jer-Yuh; Chang,
Han; Huang, Po-Hsuan; Chen, Yie-Ling; Chang, Han-Hsin
[Reprint Author]
CORPORATE SOURCE: Chung Shan Med Univ, Inst Biochem and Biotechnol, Taichung,
Taiwan
jhhc@csmu.edu.tw
SOURCE: Journal of Biomedical Science, (MAY 2006) Vol. 13, No. 3,
pp. 373-384.
ISSN: 1021-7770.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 20 Sep 2006
Last Updated on STN: 20 Sep 2006

L6 ANSWER 11 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on
STN

ACCESSION NUMBER: 2006:64783 BIOSIS
DOCUMENT NUMBER: PREV200600063695
TITLE: Progress in Molecular and Subcellular Biology.
AUTHOR(S): MacieiraCoelho, A [Editor]
SOURCE: MacieiraCoelho, A [Editor]. (2005) Progress in Molecular and Subcellular Biology.
Publisher: SPRINGER-VERLAG BERLIN, HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY. Series: PROGRESS IN MOLECULAR AND SUBCELLULAR BIOLOGY.
ISBN: 3-540-25009-3 (H).
DOCUMENT TYPE: Book
LANGUAGE: English
ENTRY DATE: Entered STN: 11 Jan 2006
Last Updated on STN: 11 Jan 2006

L6 ANSWER 12 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2005:158240 BIOSIS
DOCUMENT NUMBER: PREV200500160052
TITLE: Identification and characterization of rat Desert hedgehog and Indian hedgehog genes in silico.
AUTHOR(S): Katoh, Yuriko [Reprint Author]; Katoh, Masaru
CORPORATE SOURCE: Sect Genet and Cell BiolChuo Ku, Natl Canc Ctr Res Inst, 5-1-1 Tsukiji, Tokyo, 1040045, Japan
mkatoh@ncc.go.jp
SOURCE: International Journal of Oncology, (February 2005) Vol. 26, No. 2, pp. 545-549. print.
ISSN: 1019-6439 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 27 Apr 2005
Last Updated on STN: 27 Apr 2005

L6 ANSWER 13 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:232182 BIOSIS
DOCUMENT NUMBER: PREV200300232182
TITLE: Hedgehog pathway activity correlates with *prostate cancer* progression and promotes tumor growth.
AUTHOR(S): Karhadkar, Sunil S. [Reprint Author]; Bova, G. Steven [Reprint Author]; Beachy, Philip A. [Reprint Author]; Berman, David M. [Reprint Author]
CORPORATE SOURCE: Baltimore, MD, USA
SOURCE: Journal of Urology, (April 2003) Vol. 169, No. 4 Supplement, pp. 162. print.
Meeting Info.: 98th Annual Meeting of the American Urological Association (AUA). Chicago, IL, USA. April 26-May 01, 2003. American Urological Association.
CODEN: JOURAA. ISSN: 0022-5347.
DOCUMENT TYPE: Conference; (Meeting)
LANGUAGE: Conference; Abstract; (Meeting Abstract)
ENTRY DATE: Entered STN: 14 May 2003
Last Updated on STN: 14 May 2003

L6 ANSWER 14 OF 28 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2000:103109 BIOSIS
DOCUMENT NUMBER: PREV200000103109
TITLE: Characterization of the human Suppressor of fused, a negative regulator of the zinc-finger transcription factor Gli.
AUTHOR(S): Stone, Donna M.; Murone, Maximilien; Luh, Shiuh-Ming; Ye, Weilan; Armanini, Mark P.; Gurney, Austin; Phillips, Heidi;

CORPORATE SOURCE: Brush, Jennifer; Goddard, Audrey; de Sauvage, Frederic J.; Rosenthal, Arnon [Reprint author]
Department of Neuroscience, Genentech, Inc., 1 DNA Way,
South San Francisco, CA, 94080, USA
SOURCE: Journal of Cell Science, (Dec., 1999) Vol. 112, No. 23, pp.
4437-4448. print.
CODEN: JNCSAI. ISSN: 0021-9533.

DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 22 Mar 2000
Last Updated on STN: 3 Jan 2002

L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:319203 CAPLUS
TITLE: Hedgehog signaling in the prostate
AUTHOR(S): Shaw, Aubie; Bushman, Wade
CORPORATE SOURCE: McArdle Laboratory for Cancer Research and Department
of Surgery, University of Wisconsin, Madison, WI, USA
SOURCE: Journal of Urology (New York, NY, United States)
(2007), 177(3), 832-838
CODEN: JOURAA; ISSN: 0022-5347
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:735138 CAPLUS
DOCUMENT NUMBER: 145:245909
TITLE: Perlecan signaling: Helping hedgehog stimulate
prostate cancer growth
AUTHOR(S): Datta, Sumana; Pierce, Michael; Datta, Milton W.
CORPORATE SOURCE: Department of Biochemistry and Biophysics, Department
of Biology, Texas A&M University, College Station, TX,
77843-2128, USA
SOURCE: International Journal of Biochemistry & Cell Biology
(2006), 38(11), 1855-1861
CODEN: IJBBFU; ISSN: 1357-2725
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:712801 CAPLUS
DOCUMENT NUMBER: 146:97768
TITLE: A mouse *prostate cancer* model
induced by hedgehog overexpression
AUTHOR(S): Chen, Bo-Yie; Lin, David Pei-Cheng; Liu, Jer-Yuh;
Chang, Han; Huang, Po-Hsuan; Chen, Yie-Ling; Chang,
Han-Hsin
CORPORATE SOURCE: Institute of Biochemistry and Biotechnology, Chung
Shan Medical University, Taichung, Taiwan
SOURCE: Journal of Biomedical Science (Dordrecht, Netherlands)
(2006), 13(3), 373-384
CODEN: JBCIEA; ISSN: 1021-7770
PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:590255 CAPLUS
DOCUMENT NUMBER: 143:170258
TITLE: Hedgehog signaling in *prostate*
cancer
AUTHOR(S): Xie, Jingwu
CORPORATE SOURCE: Sealy Centers for Cancer Cell Biology and Environmental Health, Department of Pharmacology and Toxicology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555-1048, USA
SOURCE: Future Oncology (2005), 1(3), 331-338
PUBLISHER: Future Medicine Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:151829 CAPLUS
DOCUMENT NUMBER: 143:147347
TITLE: Identification and characterization of rat Desert hedgehog and Indian hedgehog genes in silico
AUTHOR(S): Katoh, Yuriko; Katoh, Masaru
CORPORATE SOURCE: M+M Medical BioInformatics, Hongo, 113-0033, Japan
SOURCE: International Journal of Oncology (2005), 26(2), 545-549
PUBLISHER: International Journal of Oncology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:41652 CAPLUS
DOCUMENT NUMBER: 132:178471
TITLE: Characterization of the human Suppressor of fused, a negative regulator of the zinc-finger transcription factor gli
AUTHOR(S): Stone, Donna M.; Murone, Maximilien; Luoh, Shiu-Ming; Ye, Weilan; Armanini, Mark P.; Gurney, Austin; Phillips, Heidi; Brush, Jennifer; Goddard, Audrey; De Sauvage, Frederic J.; Rosenthal, Arnon
CORPORATE SOURCE: Department of Neuroscience, Genentech, Inc. 1 DNA Way, South San Francisco, CA, 94080, USA
SOURCE: Journal of Cell Science (1999), 112(23), 4437-4448
PUBLISHER: Company of Biologists Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 28 EMBASE COPYRIGHT (c) 2007 Elsevier B.V.. All rights reserved on STN
ACCESSION NUMBER: 2007076238 EMBASE
TITLE: Hedgehog Signaling in the Prostate.
AUTHOR: Shaw A.; Bushman W.
CORPORATE SOURCE: W. Bushman, McArdle Laboratory for Cancer Research, Department of Surgery, University of Wisconsin, Madison, WI, United States. bushman@surgery.wisc.edu
SOURCE: Journal of Urology, (2007) Vol. 177, No. 3, pp. 832-838. .
Refs: 42

PUBLISHER IDENT.: ISSN: 0022-5347 CODEN: JOURAA
S 0022-5347(06)02739-X
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 016 Cancer
028 Urology and Nephrology
030 Pharmacology
037 Drug Literature Index

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20 Mar 2007
Last Updated on STN: 20 Mar 2007

L6 ANSWER 22 OF 28 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2006463886 EMBASE
TITLE: Perlecan signaling: Helping hedgehog stimulate **prostate cancer** growth.
AUTHOR: Datta S.; Pierce M.; Datta M.W.
CORPORATE SOURCE: S. Datta, Department of Biochemistry and Biophysics, Department of Biology, Texas A and M University, MS 2128, College Station, TX 77843-2128, United States.
sumad@tamu.edu
SOURCE: International Journal of Biochemistry and Cell Biology, (2006) Vol. 38, No. 11, pp. 1855-1861. .
Refs: 19
ISSN: 1357-2725 CODEN: IJBBFU
PUBLISHER IDENT.: S 1357-2725(06)00126-9
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; (Short Survey)
FILE SEGMENT: 016 Cancer
029 Clinical Biochemistry

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 2 Oct 2006
Last Updated on STN: 2 Oct 2006

L6 ANSWER 23 OF 28 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2006446407 EMBASE
TITLE: Targeting the **Hedgehog signaling pathway** with small molecules.
AUTHOR: Kiselyov A.S.
CORPORATE SOURCE: A.S. Kiselyov, Small Molecule Drug Discovery, ChemDiv, Inc., 11558 Sorrento Valley Road, San Diego, CA 92121, United States. ask@chemdiv.com
SOURCE: Anti-Cancer Agents in Medicinal Chemistry, (2006) Vol. 6, No. 5, pp. 445-449. .
Refs: 56
ISSN: 1871-5206
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 016 Cancer
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 11 Oct 2006
Last Updated on STN: 11 Oct 2006

L6 ANSWER 24 OF 28 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2006231252 EMBASE

TITLE: A mouse **prostate cancer** model induced by Hedgehog overexpression.
AUTHOR: Chen B.-Y.; Lin D.P.-C.; Liu J.-Y.; Chang H.; Huang P.-H.;
Chen Y.-L.; Chang H.-H.
CORPORATE SOURCE: H.-H. Chang, Institute of Nutrition, Chung Shan Medical University, Taichung, Taiwan, Province of China.
jhhc@csmu.edu.tw
SOURCE: Journal of Biomedical Science, (2006) Vol. 13, No. 3, pp. 373-384.
Refs: 42
ISSN: 1021-7770 CODEN: JBCIEA
COUNTRY: Switzerland
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
028 Urology and Nephrology
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 27 Jun 2006
Last Updated on STN: 27 Jun 2006

L6 ANSWER 25 OF 28 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2005170284 EMBASE
TITLE: The **Hedgehog signaling pathway** as a target for anticancer drug discovery.
AUTHOR: Borzillo G.V.; Lippa B.
CORPORATE SOURCE: G.V. Borzillo, Pfizer Global Research Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, United States. gary_v_borzillo@groton.pfizer.com
SOURCE: Current Topics in Medicinal Chemistry, (2005) Vol. 5, No. 2, pp. 147-157.
Refs: 60
ISSN: 1568-0266 CODEN: CTMCCL
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
016 Cancer
022 Human Genetics
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 5 May 2005
Last Updated on STN: 5 May 2005

L6 ANSWER 26 OF 28 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2000082263 EMBASE
TITLE: Characterization of the human Suppressor of fused, a negative regulator of the zinc-finger transcription factor Gli.
AUTHOR: Stone D.M.; Murone M.; Luoh S.-M.; Ye W.; Armanini M.P.; Gurney A.; Phillips H.; Brush J.; Goddard A.; De Sauvage F.J.; Rosenthal A.
CORPORATE SOURCE: A. Rosenthal, Department of Neuroscience, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, United States. ar@gene.com
SOURCE: Journal of Cell Science, (1999) Vol. 112, No. 23, pp. 4437-4448.
Refs: 73
ISSN: 0021-9533 CODEN: JNCSAI
COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
021 Developmental Biology and Teratology
022 Human Genetics
029 Clinical Biochemistry
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 16 Mar 2000
Last Updated on STN: 16 Mar 2000

L6 ANSWER 27 OF 28 TOXCENTER COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:18855 TOXCENTER
COPYRIGHT: Copyright 2007 ACS
DOCUMENT NUMBER: CA14606097768A
TITLE: A mouse *prostate cancer* model induced by hedgehog overexpression
AUTHOR(S): Chen, Bo-Yie; Lin, David Pei-Cheng; Liu, Jer-Yuh; Chang, Han; Huang, Po-Hsuan; Chen, Yie-Ling; Chang, Han-Hsin
CORPORATE SOURCE: Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan.
SOURCE: Journal of Biomedical Science (Dordrecht, Netherlands), (2006) Vol. 13, No. 3, pp. 373-384.
CODEN: JBCIEA. ISSN: 1021-7770.
COUNTRY: TAIWAN, PROVINCE OF CHINA
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2006:712801
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Jan 2007
Last Updated on STN: 30 Jan 2007

L6 ANSWER 28 OF 28 TOXCENTER COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:187202 TOXCENTER
COPYRIGHT: Copyright 2007 ACS
DOCUMENT NUMBER: CA14310170258D
TITLE: Hedgehog signaling in *prostate cancer*
AUTHOR(S): Xie, Jingwu
CORPORATE SOURCE: Sealy Centers for Cancer Cell Biology and Environmental Health, Department of Pharmacology and Toxicology, University of Texas Medical Branch at Galveston, Galveston, TX, 77555-1048, USA.
SOURCE: Future Oncology, (2005) Vol. 1, No. 3, pp. 331-338.
CODEN: FOUNBN. ISSN: 1479-6694.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2005:590255
LANGUAGE: English
ENTRY DATE: Entered STN: 12 Jul 2005
Last Updated on STN: 30 Aug 2005

=> d his

(FILE 'HOME' ENTERED AT 13:08:57 ON 11 MAY 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, TOXCENTER' ENTERED AT 13:09:15 ON
11 MAY 2007

L1 9336 S GNRH(W)AGONIST
L2 166220 S PROSTATE(W)CANCER
L3 377 S L1 AND L2
L4 1342 S (SHH OR HEDGEHOG) (W) (SIGNALING OR SIGNALLING) (W)PATHWAY
L5 0 S L3 AND L4
L6 28 S L2 AND L4

L7 140 S L3 AND TESTOSTERONE
L8 1238 S CYCLOPAMINE
L9 0 S L3 AND L8
L10 0 S JERVAINE
L11 592 S JERVINE
L12 1238 S L1 AND L11 OR L8
L13 0 S L1 AND L11
L14 2 S L1 AND L8
L15 2 S L1 AND (L11 OR L8)
L16 39 S DEOXOJERVINE
L17 0 S L16 AND L1

=> s l7 and (l11 or l8 or l16)
L18 0 L7 AND (L11 OR L8 OR L16)

=> d 17 100-110 abs

L7 ANSWER 100 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Treatment of prostatic cancer with **GnRH agonist** is a medical alternative to surgical castration, although hyperstimulation of the tumor can occur. We describe an unusual unwanted effect of such a treatment which unmasked a clinically silent gonadotroph adenoma. A 62-year-old man developed after the first injection of leuprorelin-depot a sudden intracranial hypertension, which was related to apoplexy of an unknown pituitary adenoma. Its gonadotroph origin was recognized after surgery by immunocytochemistry. Retrospectively, the tumor was shown to secrete in vivo both FSH and LH when on therapy with the agonist, demonstrating the lack of desensitization. **Testosterone** levels were also markedly and sustainably high when on therapy, a particularly unwanted effect in prostatic cancer. As gonadotroph adenomas occur in men in the same age group as prostatic cancer, the question is raised whether hormonal testing and pituitary imaging should be performed before starting a therapy with **GnRH agonist** in men.

L7 ANSWER 101 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Objective: The aims of the study were (i) to compare the efficacy of the two long-acting **GnRH agonists** (GnRHa) triptorelin (Trp) and leuprolide (Leu) in men with **prostate cancer** and (ii) to assess the pattern of plasma **testosterone** levels following each injection of GnRHa. Patients and Methods: 67 patients referred for **prostate cancer** not suitable for surgery were randomly allocated to two treatment regimens: 33 patients received 3.75 mg Trp i.m. at 4-week intervals for 3 months and 34 patients were treated with 3.75 mg Leu s.c. at the same rhythm of administration for 3 months. Results: Clinical data at entry and assessed monthly during follow-up did not differ between the two groups. Plasma prostate-specific antigen (PSA) and **testosterone** were measured before, 24 and 72 h after each injection of GnRHa. During treatment, PSA dropped similarly in both groups. By month 2, **testosterone** was < 1.0 nmol/l in 77 and 48% of patients treated with Trp and Leu, respectively ($p = 0.02$). 24 and 72 h after GnRHa injection, 77 (Trp) and 56% (Leu) of patients had **testosterone** < 1.0 nmol/l ($p < 0.05$). Conclusions: The second and third injections of GnRHa were not followed by a significant increase in **testosterone**. Trp induced a higher decrease in **testosterone** than did Leu. The implications in terms of survival should, however, be studied in a larger and longer study.

L7 ANSWER 102 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Observations that serum follicle-stimulating hormone (FSH) levels begin to rise after initial suppression during chronic gonadotropin-releasing hormone (**GnRH**) **agonist** treatment of men with

prostate cancer had led to speculation that FSH escape might in part account for the failure of **GnRH agonist** analogs to completely suppress spermatogenesis in normal eugonadal men. However, previous studies in healthy young men failed to report FSH escape during **GnRH agonist** treatment for up to 16 weeks. We considered the possibility that this may have been due to the insensitivity of the FSH assays. Accordingly, using highly sensitive and specific two-site directed fluorometric assays and a sustained-release **GnRH agonist** formulation, we reexamined the issue of whether serum FSH levels rise after initial suppression during chronic **GnRH agonist** treatment. Two groups of healthy normal men, 19-50 years of age, received 7.5 mg of a long-acting **GnRH agonist** microcapsule formulation (Lupron Depot; TAP Pharmaceutical Company, North Chicago, Illinois) on days 1 and 30. In addition, the subjects received either 4 or 8 mg/day **testosterone** replacement by means of a **testosterone** microcapsule injected intramuscularly on day 1. Serum luteinizing hormone (LH) and FSH levels were measured by sensitive and specific two-site directed fluorometric assays on multiple occasions during the 3-week control period and the 9-week treatment period. Serum LH levels declined to a nadir between 2 and 4 weeks and stayed suppressed throughout the remainder of the treatment period in both the 4- and 8-mg **testosterone** groups. In contrast, serum FSH levels, after reaching a nadir, began to rise towards pretreatment control levels in both treatment groups. These data provide unequivocal evidence that FSH levels escape from combined **GnRH agonist**- and **testosterone**-induced suppression in healthy young men and add to a growing body of evidence that LH and FSH can be differentially regulated in vivo. Although the mechanisms of this phenomenon remain unclear, FSH escape may be clinically relevant for the therapeutic use of **GnRH agonist** analogs for male contraception.

L7 ANSWER 103 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB The effects of 3 months treatment with the **GnRH agonist** triptorelin as a neoadjuvant to total prostatectomy in 40 men with localized prostatic cancer have been evaluated. The study included 1 patient with a stage T(1b), tumour, 25 patients with stage T2 tumours and 14 with stage T3 tumours. The patients were examined by digital rectal examination, transrectal ultrasound before and after treatment. Serum **testosterone** and prostate-specific antigen (PSA) levels were followed. The totally removed prostate gland was step-sectioned at 5-mm intervals and the whole-mount sections were assessed for tumour pathology stage (pT stage). Triptorelin treatment resulted in a significant decrease in total gland and tumour volume and in a reduction in the serum levels of PSA and **testosterone**. In comparison with the findings from a previous study, in which neoadjuvant treatment was not used, it appears that the proportion of tumours invading the margins of the surgical specimen decreased.

L7 ANSWER 104 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L7 ANSWER 105 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB The effect of combined treatment with a **GnRH agonist** (buserelin depot, BUS, 6.6 mg every 2 months) with an antiandrogen (cyproterone acetate, CPA, 300 mg day-1) or a prolactin-suppressing agent (bromocriptine, BR, 20 mg day-1) on pituitary-testicular function were studied in patients with advanced prostatic carcinoma. The patients (n = 5-6 per group) were treated in this fashion for 6 months and thereafter orchidectomized. Serum **testosterone** and gonadotrophin responses were followed during treatment, and histology and certain endocrine parameters were studied using testicular tissue obtained at orchidectomy. Serum LH was suppressed in all treatment groups from mean levels of 4-6 IU

1-1 to less than 0.1 IU 1-1, whilst serum FSH levels decreased in all groups during the first month of therapy from 4.5-7 to 1-2 IU 1-1, but recovered thereafter. Only minor increases in serum gonadotrophin levels were evident 3 months after castration. No differences in gonadotrophin responses were seen between the different treatment groups. Serum levels of **testosterone** were suppressed from 15-20 nmol 1-1 to the castrate range (.apprx. 1 nmol 1-1), in each of the treatment groups. Testicular weight decreased significantly more ($P < 0.05$) in the BUS + CPA group, compared to the other treatments. No differences were found in the testicular concentration of **testosterone**, or LH and FSH receptors between the three treatment groups. On histological examination, spermatogenesis was found to be impaired severely in all groups, with the lowest Johnsen score in the BUS + BR group (2.16 ± 0.13 , vs. 2.73 ± 0.25 with BUS alone; $P < 0.05$). Seminiferous tubular diameters were reduced similarly in all treatment groups. In conclusion, the combination of CPA or BR with BUS in the treatment of prostatic carcinoma does not potentiate the suppression of gonadotrophin or **testosterone** secretion, evidently because the **GnRH agonist** exerts a maximal suppressing effect. However, other antigenadal effects were enhanced slightly, including suppressed testicular weights by CPA and further suppression of spermatogenesis by BR.

L7 ANSWER 106 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and **testosterone** (T) responses to 6-month treatments with a gonadotropin-releasing hormone (**GnRH**) **agonist** (buserelin) and subsequent orchiectomy were studied in patients with advanced **prostate cancer**. For treatments, either an intranasal (600 µg, 3/day, n = 8) or subcutaneous depot preparation (6.6 mg every other month, n = 5) were used. A third group of patients received intranasal buserelin (400 µg, 3/day, n = 12) for 35 months. LH and FSH were measured using radioimmunoassay (RIA) and a sensitive (0.04 IU/L) immunofluorometric assay (IFMA). In addition, selected samples were analyzed for bioactive (bio) LH. The RIA-LH levels decreased 70% with intranasal treatment. In contrast, when monitored by IFMA, the reduction was greater than 90%: 0.2 to 0.3 IU/L with intranasal and 0.044 to 0.052 IU/L with depot treatment ($P < 0.01$). Gonadotropin suppression was stable up to 35 months. Bio-LH and IFMA-LH levels decreased in parallel during treatment, with no apparent changes in the bio/immuno ratio. FSH levels were suppressed temporarily during the treatments. After castration and cessation of buserelin treatment, serum LH and FSH increased rapidly in the intranasal treatment group but only marginally during 3 months in the depot group. Serum T reached the castrate range when IFMA-LH decreased below 0.5 IU/L. A further decrease in LH (<0.1 IU/L) still suppressed the intratesticular T concentration measured after orchiectomy. In conclusion, IFMA offers an improved method to monitor the antigenadotropic effect of **GnRH agonist** treatment. The results emphasize the necessity of profound LH suppression to achieve maximal inhibition of testicular androgen production.

L7 ANSWER 107 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Cancer commonly leads to weight loss associated with increased glucose production and protein breakdown. Medical or surgical castration results in decreased muscle mass, increased fat mass, and weight gain. The aim of this study was to evaluate the changes in body composition, protein metabolism, hepatic glucose production, (HGP), and basal energy expenditure in 10 men with advanced stage C and D **prostate cancer** receiving a gonadotropin-releasing hormone (**GnRH**) **agonist** (Buserelin). Metabolic parameters and nutritional status were determined at 0, 2, 6, and 12 months of therapy. Baseline measurements of plasma leucine appearance ($76.2 \pm 5.4 \mu\text{M}/\text{kg}/\text{h}$) and

HGP rates (80.1 ± 2.9 mg/m²/min) were greater than previously reported for normal volunteers. **GnRH agonist** therapy in **prostate cancer** patients was associated with a significant reduction in serum **testosterone**, dihydrotestosterone (DHT), luteinizing hormone (LH), and cortisol, and significant increases in triiodothyronine (T3) and free triiodothyronine (free T3). Neither basal energy expenditure nor plasma leucine appearance rates were changed over time, but there were significant linear reductions in HGP rates (80.1 ± 2.9 mg/m²/min, mean \pm SEM; 79.9 ± 2.3 , 73.7 ± 3.4 , 72.5 ± 2.3 ; P < .01; baseline, 2, 6, and 12 months, respectively, by repeated measures ANOVA). In all patients, significant increases in body weight, triceps skin fold, cholesterol, and fat mass were noted. Total body water content was not significantly increased after the 12-month period; therefore, the weight gain seen in these patients was water-free tissue, ie, fat mass.

L7 ANSWER 108 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB In order to assess the extent of inhibition of testicular steroidogenesis during long-term treatment of prostatic cancer with **GnRH agonist**, we measured the intratesticular levels of 5 steroid sulfate conjugates in human testis tissue removed from patients after 6 months of intranasal treatment with buserelin. The most pronounced decreases were found in **testosterone** and pregnenolone sulfates, to 1.6 and 7.1%, respectively, of concentrations measured in testis tissue from primarily orchietomized prostatic cancer patients. In contrast, clearly smaller decreases were found in three other steroid sulfates measured, those of dehydroepiandrosterone (to 26%), 17-hydroxyprogesterone (to 27%) and 5-androstene-3 β ,17 β -diol (to 62%). These results are in keeping with our previous analyses of unconjugated steroids in similar tissue samples, and indicate that testicular steroidogenesis per se is not totally blocked by long-term intranasal treatment with **GnRH agonist**. Testicular steroid sulfate conjugation may be specifically suppressed since the total concentration of these conjugates decreased more than free steroid levels in our earlier measurements.

L7 ANSWER 109 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AB Tumor flare is reported in up to 40% of patients treated with gonadotrophin-releasing hormone analogues for **prostate cancer**. In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (**GnRH**) **agonist**. The early results of this study are presented here. Thirty patients with advanced symptomatic diseases were randomized to receive either cyproterone acetate 50 or 100 mg three times daily or flutamide 250 mg three times daily given for 1 week before and during the first month of **GnRH agonist** treatment. The endocrine profiles of these patients were compared with those of historic controls treated with depot agonist alone. Three patients treated with low-dose cyproterone acetate and one with flutamide developed a transient exacerbation of their disease. No patients treated with the higher-dose cyproterone acetate regimen developed tumor flare. No patients treated with cyproterone acetate had an increase in serum **testosterone** above baseline following depot **GnRH agonist** implantation. All patients treated with flutamide had increases in serum **testosterone**, but this did not significantly increase further with implantation. This study suggests that all patients receiving **GnRH agonist** treatment should be pretreated with cyproterone acetate 100 mg three times daily for 1 week before implantation and for the first treatment month.

L7 ANSWER 110 OF 140 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights

AB reserved on STN
Seven patients suffering from prostatic cancer were treated with a slow-release D-Trp-6-LHRH preparation for a period of 24-32 months. LH, FSH, PRL and **testosterone** levels were evaluated before and at the end of treatment and then 40 days later. Baseline and GnRH-, TRH-, and HCG-stimulated hormonal values decreased after treatment. The possibility that a long-term treatment with GnRH analogues induces a sustained suppression of pituitary and testicular function is suggested.

=> d 17 1 ibib, abs

L7 ANSWER 1 OF 140 MEDLINE on STN
ACCESSION NUMBER: 2006628920 MEDLINE
DOCUMENT NUMBER: PubMed ID: 17062721
TITLE: Treatment-related osteoporosis in men with **prostate cancer**.
AUTHOR: Smith Matthew R
CORPORATE SOURCE: Massachusetts General Hospital, Boston, Massachusetts 02114, USA.. smith.matthew@mgh.harvard.edu
SOURCE: Clinical cancer research : an official journal of the American Association for Cancer Research, (2006 Oct 15) Vol. 12, No. 20 Pt 2, pp. 6315s-6319s. Ref: 49
Journal code: 9502500. ISSN: 1078-0432.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200611
ENTRY DATE: Entered STN: 26 Oct 2006
Last Updated on STN: 19 Dec 2006
Entered Medline: 29 Nov 2006

AB The intended therapeutic effect of gonadotropin-releasing hormone (**GnRH**) **agonists** is hypogonadism, a major cause of acquired osteoporosis in men. Consistent with this observation, **GnRH agonists** increase bone turnover and decrease bone mineral density, a surrogate for fracture risk. Large claims-based analyses and other retrospective studies provide compelling evidence that **GnRH agonists** increase risk of clinical fractures. Estrogens play a central role in homeostasis of the normal male skeleton, and estrogen deficiency rather than **testosterone** deficiency seems to be primarily responsible for the adverse skeletal effects of **GnRH agonists**. In randomized controlled trials, bisphosphonates (pamidronate and zoledronic acid) and selective estrogen receptor modulators (raloxifene and toremifene) increased bone mineral density in **GnRH agonist**-treated men. Two ongoing large randomized placebo-controlled studies will prospectively define fracture outcomes in men with **prostate cancer** and assess the efficacy of novel pharmacologic interventions (AMG162, toremifene) during **GnRH agonist** treatment.

=> d his

(FILE 'HOME' ENTERED AT 13:08:57 ON 11 MAY 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, TOXCENTER' ENTERED AT 13:09:15 ON 11 MAY 2007

L1 9336 S GNRH(W)AGONIST
L2 166220 S PROSTATE(W)CANCER
L3 377 S L1 AND L2
L4 1342 S (SHH OR HEDGEHOG)(W) (SIGNALING OR SIGNALLING)(W)PATHWAY
L5 0 S L3 AND L4

L6 28 S L2 AND L4
L7 140 S L3 AND TESTOSTERONE
L8 1238 S CYCLOPAMINE
L9 0 S L3 AND L8
L10 0 S JERVAINE
L11 592 S JERVINE
L12 1238 S L1 AND L11 OR L8
L13 0 S L1 AND L11
L14 2 S L1 AND L8
L15 2 S L1 AND (L11 OR L8)
L16 39 S DEOXOJERVINE
L17 0 S L16 AND L1
L18 0 S L7 AND (L11 OR L8 OR L16)

=> l2 and (l11 or l8 or l16)

L2 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (>).

=> s l2 and (l11 or l8 or l16)

L19 54 L2 AND (L11 OR L8 OR L16)

=> s l19 and treatment

L20 27 L19 AND TREATMENT

=> d l20 1-27 ibib

L20 ANSWER 1 OF 27 MEDLINE on STN

ACCESSION NUMBER: 2007162429 IN-PROCESS

DOCUMENT NUMBER: PubMed ID: 17363490

TITLE: Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and *cyclopamine* cooperatively improves the cytotoxic effects of docetaxel on metastatic *prostate cancer* cells.

AUTHOR: Mimeaule Murielle; Johansson Sonny L; Vankatraman Ganesh; Moore Eric; Henichart Jean-Pierre; Depreux Patrick; Lin Ming-Fong; Batra Surinder K

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, 985870 Nebraska Medical Center, Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE 68198-5870, USA.

CONTRACT NUMBER: CA 88184 (NCI)

SOURCE: Molecular cancer therapeutics, (2007 Mar) Vol. 6, No. 3, pp. 967-78.

JOURNAL CODE: 101132535. ISSN: 1535-7163.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)

LANGUAGE: English

FILE SEGMENT: NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals

ENTRY DATE: Entered STN: 17 Mar 2007

Last Updated on STN: 31 Mar 2007

L20 ANSWER 2 OF 27 MEDLINE on STN

ACCESSION NUMBER: 2007097713 MEDLINE

DOCUMENT NUMBER: PubMed ID: 17296441

TITLE: Lack of demonstrable autocrine hedgehog signaling in human *prostate cancer* cell lines.

AUTHOR: Zhang Jingxian; Lipinski Robert; Shaw Aubie; Gipp Jerry; Bushman Wade

CORPORATE SOURCE: Department of Surgery and McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, Wisconsin

SOURCE: 53792, USA.
The Journal of urology, (2007 Mar) Vol. 177, No. 3, pp.
1179-85.
Journal code: 0376374. ISSN: 0022-5347.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)

LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200704
ENTRY DATE: Entered STN: 14 Feb 2007
Last Updated on STN: 4 Apr 2007
Entered Medline: 3 Apr 2007

L20 ANSWER 3 OF 27 MEDLINE on STN
ACCESSION NUMBER: 2007097632 MEDLINE
DOCUMENT NUMBER: PubMed ID: 17296352
TITLE: Hedgehog signaling in the prostate.
AUTHOR: Shaw Aubie; Bushman Wade
CORPORATE SOURCE: McArdle Laboratory for Cancer Research and Department of
Surgery, University of Wisconsin, Madison, Wisconsin 53792,
USA.

CONTRACT NUMBER: CA095386 (NCI)
SOURCE: The Journal of urology, (2007 Mar) Vol. 177, No. 3, pp.
832-8. Ref: 42
Journal code: 0376374. ISSN: 0022-5347.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)
General Review; (REVIEW)

LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200704
ENTRY DATE: Entered STN: 14 Feb 2007
Last Updated on STN: 4 Apr 2007
Entered Medline: 3 Apr 2007

L20 ANSWER 4 OF 27 MEDLINE on STN
ACCESSION NUMBER: 2006064655 MEDLINE
DOCUMENT NUMBER: PubMed ID: 16108016
TITLE: Cytotoxic effects induced by a combination of
cyclopamine and gefitinib, the selective hedgehog
and epidermal growth factor receptor signaling inhibitors,
in *prostate cancer* cells.
AUTHOR: Mimeaule Murielle; Moore Erik; Moniaux Nicolas; Henichart
Jean-Pierre; Depreux Patrick; Lin Ming-Fong; Batra Surinder
K
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology,
University of Nebraska Medical Center, College of Medicine,
Omaha, NE 68198-5870, USA.

SOURCE: International journal of cancer. Journal international du
cancer, (2006 Feb 15) Vol. 118, No. 4, pp. 1022-31.
Journal code: 0042124. ISSN: 0020-7136.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200602
ENTRY DATE: Entered STN: 2 Feb 2006
Last Updated on STN: 1 Mar 2006
Entered Medline: 28 Feb 2006

L20 ANSWER 5 OF 27 MEDLINE on STN
ACCESSION NUMBER: 2004501731 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15361885
TITLE: Hedgehog signalling in prostate regeneration, neoplasia and metastasis.
AUTHOR: Karhadkar Sunil S; Bova G Steven; Abdallah Nadia; Dhara Surajit; Gardner Dale; Maitra Anirban; Isaacs John T; Berman David M; Beachy Philip A
CORPORATE SOURCE: Department of Molecular Biology and Genetics and the Howard Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
SOURCE: Nature, (2004 Oct 7) Vol. 431, No. 7009, pp. 707-12.
Electronic Publication: 2004-09-12.
Journal code: 0410462. E-ISSN: 1476-4687.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200410
ENTRY DATE: Entered STN: 8 Oct 2004
Last Updated on STN: 29 Oct 2004
Entered Medline: 28 Oct 2004

L20 ANSWER 6 OF 27 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:288686 BIOSIS
DOCUMENT NUMBER: PREV200700288786
TITLE: Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and *cyclopamine* cooperatively improves the cytotoxic effects of docetaxel on metastatic *prostate cancer* cells.
AUTHOR(S): Mimeaule, Murielle; Johansson, Sonny L.; Vankatraman, Ganesh; Moore, Eric; Henichart, Jean-Pierre; Depreux, Patrick; Lin, Ming-Fong; Batra, Surinder K. [Reprint Author]
CORPORATE SOURCE: Univ Nebraska, Med Ctr, Eppley Inst Res Canc and Allied Dis, Dept Biochem and Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA
sbatra@unmc.edu
SOURCE: Molecular Cancer Therapeutics, (MAR 2007) Vol. 6, No. 3, pp. 967-978.
ISSN: 1535-7163.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 2 May 2007
Last Updated on STN: 2 May 2007

L20 ANSWER 7 OF 27 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:267439 BIOSIS
DOCUMENT NUMBER: PREV200700258796
TITLE: Sonic hedgehog signaling in mantle cell lymphoma.
AUTHOR(S): Hegde, Ganapati V. [Reprint Author]; Emanuel, Katy; Joshi, Avadhut D.; Munger, Corey M.; Weisenburger, Dennis D.; Vose, Julie M.; Joshi, Shantaram S.
CORPORATE SOURCE: Univ Nebraska, Med Ctr, Omaha, NE USA
SOURCE: Blood, (NOV 16 2006) Vol. 108, No. 11, Part 1, pp. 580A.
Meeting Info.: 48th Annual Meeting of the American-Society-of-Hematology. Orlando, FL, USA. December 09 -12, 2006. Amer Soc Hematol.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; (Meeting Poster)

LANGUAGE: English
ENTRY DATE: Entered STN: 25 Apr 2007
Last Updated on STN: 25 Apr 2007

L20 ANSWER 8 OF 27 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:265780 BIOSIS
DOCUMENT NUMBER: PREV200700257137
TITLE: Hedgehog pathway: A new target for B-Cell lymphomas and multiple myeloma.
AUTHOR(S): Dierks, Christine [Reprint Author]; Grbic, Jovana; Zirlik, Katja; Mertelsmann, Roland H.; Warmuth, Markus
CORPORATE SOURCE: GNF, In Vivo Oncol, San Diego, CA USA
SOURCE: Blood, (NOV 16 2006) Vol. 108, No. 11, Part 1, pp. 119A-120A.
Meeting Info.: 48th Annual Meeting of the American-Society-of-Hematology. Orlando, FL, USA. December 09 -12, 2006. Amer Soc Hematol.
CODEN: BLOOA. ISSN: 0006-4971.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)

LANGUAGE: English
ENTRY DATE: Entered STN: 25 Apr 2007
Last Updated on STN: 25 Apr 2007

L20 ANSWER 9 OF 27 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:206556 BIOSIS
DOCUMENT NUMBER: PREV200700206933
TITLE: Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines.
AUTHOR(S): Zhang, Jingxian; Lipinski, Robert; Shaw, Aubie; Gipp, Jerry; Bushman, Wade [Reprint Author]
CORPORATE SOURCE: Univ Wisconsin, Dept Surg, 600 Highland Ave, Madison, WI 53792 USA
bushman@surgery.wisc.edu
SOURCE: Journal of Urology, (MAR 2007) Vol. 177, No. 3, pp. 1179-1185.
CODEN: JOURAA. ISSN: 0022-5347.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 21 Mar 2007
Last Updated on STN: 21 Mar 2007

L20 ANSWER 10 OF 27 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2007:206502 BIOSIS
DOCUMENT NUMBER: PREV200700206879
TITLE: Hedgehog signaling in the prostate.
AUTHOR(S): Shaw, Aubie; Bushman, Wade [Reprint Author]
CORPORATE SOURCE: Univ Wisconsin, Dept Surg, 600 Highland Ave, Madison, WI 53792 USA
bushman@surgery.wisc.edu
SOURCE: Journal of Urology, (MAR 2007) Vol. 177, No. 3, pp. 832-838.
CODEN: JOURAA. ISSN: 0022-5347.
DOCUMENT TYPE: Article
LANGUAGE: General Review; (Literature Review)
ENTRY DATE: Entered STN: 21 Mar 2007
Last Updated on STN: 21 Mar 2007

L20 ANSWER 11 OF 27 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 2006:240573 BIOSIS
DOCUMENT NUMBER: PREV200600238877

TITLE: Cytotoxic effects induced by a combination of **cyclopamine** and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in **prostate cancer** cells.

AUTHOR(S): Mimeault, Murielle; Moore, Erik; Moniaux, Nicolas; Henichart, Jean-Pierre; Depreux, Patrick; Lin, Ming-Fong; Batra, Surinder K. [Reprint Author]

CORPORATE SOURCE: Univ Nebraska, Med Ctr, Dept Biochem and Mol Biol, Nebraska Med Ctr 985870, 600 S 42nd St, Omaha, NE 68198 USA
sbatra@unmc.edu

SOURCE: International Journal of Cancer, (FEB 15 2006) Vol. 118, No. 4, pp. 1022-1031.
CODEN: IJCNNAW. ISSN: 0020-7136.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 19 Apr 2006
Last Updated on STN: 19 Apr 2006

L20 ANSWER 12 OF 27 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2000:211718 BIOSIS

DOCUMENT NUMBER: PREV200000211718

TITLE: Inhibition of prostate morphogenesis by the Sonic hedgehog pathway inhibitor **cyclopamine**.

AUTHOR(S): Berman, David M. [Reprint author]; Chen, James K. [Reprint author]; Beachy, Philip A. [Reprint author]

CORPORATE SOURCE: Baltimore, MD, USA

SOURCE: Journal of Urology, (April, 2000) Vol. 163, No. 4 Suppl., pp. 204. print.
Meeting Info.: 95th Annual Meeting of the American Urological Association, Inc. Atlanta, Georgia, USA. April 29, 2000-May 04, 1999.
CODEN: JOURAA. ISSN: 0022-5347.

DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)

LANGUAGE: English

ENTRY DATE: Entered STN: 24 May 2000
Last Updated on STN: 5 Jan 2002

L20 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:319214 CAPLUS

TITLE: Lack of demonstrable autocrine hedgehog signaling in human **prostate cancer** cell lines

AUTHOR(S): Zhang, Jingxian; Lipinski, Robert; Shaw, Aubie; Gipp, Jerry; Bushman, Wade

CORPORATE SOURCE: Department of Surgery and McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI, USA

SOURCE: Journal of Urology (New York, NY, United States) (2007), 177(3), 1179-1185
CODEN: JOURAA; ISSN: 0022-5347

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:319203 CAPLUS

TITLE: Hedgehog signaling in the prostate

AUTHOR(S): Shaw, Aubie; Bushman, Wade

CORPORATE SOURCE: McArdle Laboratory for Cancer Research and Department of Surgery, University of Wisconsin, Madison, WI, USA

SOURCE: Journal of Urology (New York, NY, United States)
(2007), 177(3), 832-838
CODEN: JOURAA; ISSN: 0022-5347

PUBLISHER: Elsevier
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:289484 CAPLUS
DOCUMENT NUMBER: 146:394607
TITLE: Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and **cyclopamine** cooperatively improves the cytotoxic effects of docetaxel on metastatic **prostate cancer** cells
AUTHOR(S): Mimeaule, Murielle; Johansson, Sonny L.; Vankatraman, Ganesh; Moore, Eric; Henichart, Jean-Pierre; Depreux, Patrick; Lin, Ming-Fong; Batra, Surinder K.
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, 68198-5870, USA
SOURCE: Molecular Cancer Therapeutics (2007), 6(3), 967-978
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:132126 CAPLUS
DOCUMENT NUMBER: 144:163772
TITLE: Cytotoxic effects induced by a combination of **cyclopamine** and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in **prostate cancer** cells
AUTHOR(S): Mimeaule, Murielle; Moore, Erik; Moniaux, Nicolas; Henichart, Jean-Pierre; Depreux, Patrick; Lin, Ming-Fong; Batra, Surinder K.
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
SOURCE: International Journal of Cancer (2005), Volume Date 2006, 118(4), 1022-1031
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:527384 CAPLUS
DOCUMENT NUMBER: 143:53470
TITLE: Compositions of small interfering RNAs for inhibiting hedgehog and Gli signaling pathway and uses for cancer therapy
INVENTOR(S): Ruiz i Altaba, Ariel; Datta, Suma; Datta, Milton USA
PATENT ASSIGNEE(S):
SOURCE: U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 456,954.

DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:

CODEN: USXXCO

Patent

English

5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005130922	A1	20050616	US 2004-927951	20040829
US 6238876	B1	20010529	US 1998-102491	19980622
US 2003100032	A1	20030529	US 2001-825155	20010403
US 2004092010	A1	20040513	US 2003-414267	20030415
US 2004072345	A1	20040415	US 2003-456954	20030606
US 2007009530	A1	20070111	US 2006-407702	20060420
PRIORITY APPLN. INFO.:			US 1997-50286P	P 19970620
			US 1998-102491	A1 19980622
			US 2001-825155	B2 20010403
			US 2002-372508P	P 20020415
			US 2003-414267	A2 20030415
			US 2003-456954	A2 20030606
			US 2004-927951	A2 20040829
			US 2004-930723	A2 20040831

L20 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:450836 CAPLUS
DOCUMENT NUMBER: 143:19953
TITLE: SHH/GLI pathway-based methods and compositions for treatment and diagnosis of cancer
INVENTOR(S): Ruiz i Altaba, Ariel; Sanchez, Pilar; Rom, William; Wong, Kam-Meng Tchou
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 456,954.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005112707	A1	20050526	US 2004-930723	20040831
US 6238876	B1	20010529	US 1998-102491	19980622
US 2003100032	A1	20030529	US 2001-825155	20010403
US 2004092010	A1	20040513	US 2003-414267	20030415
US 2004072345	A1	20040415	US 2003-456954	20030606
US 2007009530	A1	20070111	US 2006-407702	20060420
PRIORITY APPLN. INFO.:			US 1997-50286P	P 19970620
			US 1998-102491	A1 19980622
			US 2001-825155	A2 20010403
			US 2002-372508P	P 20020415
			US 2003-414267	A2 20030415
			US 2003-456954	A2 20030606
			US 2004-927951	A2 20040829
			US 2004-930723	A2 20040831

L20 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:316305 CAPLUS
DOCUMENT NUMBER: 142:367657
TITLE: Hedgehog protein signaling in prostate regeneration, neoplasia and metastasis
INVENTOR(S): Beachy, Philip A.; Berman, David M.; Karhadkar, Sunil S.
PATENT ASSIGNEE(S): The Johns Hopkins University, USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005032343	A2	20050414	WO 2004-US32087	20041001
WO 2005032343	A3	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-507588P P 20031001
US 2004-552542P P 20040312

L20 ANSWER 20 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2007076261 EMBASE

TITLE: Lack of Demonstrable Autocrine Hedgehog Signaling in Human *Prostate Cancer* Cell Lines.

AUTHOR: Zhang J.; Lipinski R.; Shaw A.; Gipp J.; Bushman W.

CORPORATE SOURCE: W. Bushman, Department of Surgery, McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI, United States. bushman@surgery.wisc.edu

SOURCE: Journal of Urology, (2007) Vol. 177, No. 3, pp. 1179-1185.

Refs: 18

ISSN: 0022-5347 CODEN: JOURAA

PUBLISHER IDENT.: S 0022-5347(06)02768-6

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 016 Cancer

028 Urology and Nephrology

030 Pharmacology

037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20 Mar 2007

Last Updated on STN: 20 Mar 2007

L20 ANSWER 21 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2007076238 EMBASE

TITLE: Hedgehog Signaling in the Prostate.

AUTHOR: Shaw A.; Bushman W.

CORPORATE SOURCE: W. Bushman, McArdle Laboratory for Cancer Research, Department of Surgery, University of Wisconsin, Madison, WI, United States. bushman@surgery.wisc.edu

SOURCE: Journal of Urology, (2007) Vol. 177, No. 3, pp. 832-838.

Refs: 42

ISSN: 0022-5347 CODEN: JOURAA

PUBLISHER IDENT.: S 0022-5347(06)02739-X

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 016 Cancer
 028 Urology and Nephrology
 030 Pharmacology
 037 Drug Literature Index

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20 Mar 2007
 Last Updated on STN: 20 Mar 2007

L20 ANSWER 22 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2006054553 EMBASE

TITLE: Cytotoxic effects induced by a combination of cydopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in *prostate cancer* cells.

AUTHOR: Mimeaule M.; Moore E.; Moniaux N.; Henichart J.-P.; Depreux P.; Lin M.-F.; Batra S.K.

CORPORATE SOURCE: S.K. Batra, Department of Biochemistry and Molecular Biology, 985870 Nebraska Medical Center, University of Nebraska Medical Center, Omaha, NE 68198-5870, United States. sbatra@unmc.edu

SOURCE: International Journal of Cancer, (15 Feb 2006) Vol. 118, No. 4, pp. 1022-1031.
Refs: 63
ISSN: 0020-7136 E-ISSN: 1097-0215 CODEN: IJCNAW

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 016 Cancer
 030 Pharmacology
 037 Drug Literature Index

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 3 Mar 2006
 Last Updated on STN: 3 Mar 2006

L20 ANSWER 23 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005175766 EMBASE

TITLE: Therapeutic targeting of the Hedgehog-GLI pathway in *prostate cancer*.

AUTHOR: Sanchez P.; Clement V.; Ruiz I Altaba A.

CORPORATE SOURCE: A. Ruiz I Altaba, Dept. of Genetic Med. and Devmt., University of Geneva Medical School, 8242 CMU, 1 rue Michel Servet, CH-1211 Geneva 4, Switzerland.
Ariel.RuizAltaba@medecine.unige.ch

SOURCE: Cancer Research, (15 Apr 2005) Vol. 65, No. 8, pp. 2990-2992.
Refs: 21
ISSN: 0008-5472 CODEN: CNREA8

COUNTRY: United States

DOCUMENT TYPE: Journal; General Review

FILE SEGMENT: 016 Cancer
 025 Hematology
 028 Urology and Nephrology
 030 Pharmacology
 037 Drug Literature Index

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 19 May 2005
 Last Updated on STN: 19 May 2005

L20 ANSWER 24 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2005170284 EMBASE
TITLE: The Hedgehog signaling pathway as a target for anticancer drug discovery.
AUTHOR: Borzillo G.V.; Lippa B.
CORPORATE SOURCE: G.V. Borzillo, Pfizer Global Research Development, Groton Laboratories, Eastern Point Road, Groton, CT 06340, United States. gary_v_borzillo@groton(pfizer.com)
SOURCE: Current Topics in Medicinal Chemistry, (2005) Vol. 5, No. 2, pp. 147-157.
Refs: 60
ISSN: 1568-0266 CODEN: CTMCL
COUNTRY: Netherlands
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
016 Cancer
022 Human Genetics
029 Clinical Biochemistry
030 Pharmacology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 5 May 2005
Last Updated on STN: 5 May 2005

L20 ANSWER 25 OF 27 TOXCENTER COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:42424 TOXCENTER
COPYRIGHT: Copyright 2007 ACS
DOCUMENT NUMBER: CA14410163772J
TITLE: Cytotoxic effects induced by a combination of **cyclopamine** and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in **prostate cancer** cells
AUTHOR(S): Mimeaule, Murielle; Moore, Erik; Moniaux, Nicolas; Henichart, Jean-Pierre; Depreux, Patrick; Lin, Ming-Fong; Batra, Surinder K.
CORPORATE SOURCE: Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
SOURCE: International Journal of Cancer, (2005) Vol. 118, No. 4, pp. 1022-1031.
CODEN: IJCNW. ISSN: 0020-7136.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Journal
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2006:132126
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Feb 2006
Last Updated on STN: 28 Feb 2006

L20 ANSWER 26 OF 27 TOXCENTER COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:161687 TOXCENTER
COPYRIGHT: Copyright 2007 ACS
DOCUMENT NUMBER: CA14302019953F
TITLE: SHH/GLI pathway-based methods and compositions for **treatment** and diagnosis of cancer
AUTHOR(S): Ruiz i Altaba, Ariel; Sanchez, Pilar; Rom, William; Wong, Kam-Meng Tchou
PATENT INFORMATION: US 2005112707 A1 26 May 2005
SOURCE: (2005) U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 456,954.
CODEN: USXXCO.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS

OTHER SOURCE: CAPLUS 2005:450836
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Jun 2005
Last Updated on STN: 16 Jan 2007

L20 ANSWER 27 OF 27 TOXCENTER COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:127620 TOXCENTER
COPYRIGHT: Copyright 2007 ACS
DOCUMENT NUMBER: CA14220367657U
TITLE: Hedgehog protein signaling in prostate regeneration,
neoplasia and metastasis
AUTHOR(S): Beachy, Philip A.; Berman, David M.; Karhadkar, Sunil S.
CORPORATE SOURCE: ASSIGNEE: The Johns Hopkins University
PATENT INFORMATION: WO 2005032343 A2 14 Apr 2005
SOURCE: (2005) PCT Int. Appl., 68 pp.
CODEN: PIXXD2.
COUNTRY: UNITED STATES
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2005:316305
LANGUAGE: English
ENTRY DATE: Entered STN: 3 May 2005
Last Updated on STN: 23 Jan 2007

=>
=> d his

(FILE 'HOME' ENTERED AT 13:08:57 ON 11 MAY 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE, TOXCENTER' ENTERED AT 13:09:15 ON
11 MAY 2007

L1 9336 S GNRH(W)AGONIST
L2 166220 S PROSTATE(W)CANCER
L3 377 S L1 AND L2
L4 1342 S (SHH OR HEDGEHOG) (W) (SIGNALING OR SIGNALLING) (W) PATHWAY
L5 0 S L3 AND L4
L6 28 S L2 AND L4
L7 140 S L3 AND TESTOSTERONE
L8 1238 S CYCLOPAMINE
L9 0 S L3 AND L8
L10 0 S JERVAINE
L11 592 S JERVINE
L12 1238 S L1 AND L11 OR L8
L13 0 S L1 AND L11
L14 2 S L1 AND L8
L15 2 S L1 AND (L11 OR L8)
L16 39 S DEOXOJERVINE
L17 0 S L16 AND L1
L18 0 S L7 AND (L11 OR L8 OR L16)
L19 54 S L2 AND (L11 OR L8 OR L16)
L20 27 S L19 AND TREATMENT